⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861623 | 1.00 | — | — | |
| SCHEMBL1299498 | 1.00 | — | — | |
| SCHEMBL1864723 | 0.90 | — | — | |
| SCHEMBL1863181 | 0.90 | — | — | |
| SCHEMBL218013 | 0.90 | — | — | |
| SCHEMBL2535651 | 0.88 | — | — | |
| SCHEMBL9122289 | 0.88 | TSHR (0.35) | — | |
| SCHEMBL21222731 | 0.88 | — | — | |
| SCHEMBL1144431 | 0.88 | — | — | |
| SCHEMBL11067279 | 0.88 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114814-A1 | JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2024-06-06 | — | — | WO | claimed |
| EP-4370206-A1 | ESTERS OF 7-COOH CBD DERIVATIVES AND THEIR USE AS PREVENTION, PROPHYLAXIS OF PROGRESSION, AND/OR TREATMENT OF NEUROGENERATIVE DISEASES | Receptorpharma Inc S-Corp (US) | 2024-05-22 | — | — | EP | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| WO-2024099337-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS, AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-16 | — | — | WO | claimed |
| US-11981686-B2 | Urea compound having substituent | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-14 | — | — | US | claimed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL PORTELA & CA SA (PT) | 2023-05-04 | — | — | US | claimed |
| EP-4168394-A1 | AMIDOPYRIMIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-26 | — | — | EP | claimed |
| CN-115867541-A | Aminopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-03-28 | — | — | CN | claimed |
| WO-1998041525-A1 | PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | claimed |
| EP-0322242-B1 | Adenosine derivatives | GLAXO GROUP LTD (GB) | 1998-04-01 | — | — | EP | claimed |
| EP-0635014-B1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LTD (GB) | 1996-01-17 | — | — | EP | claimed |
| EP-0635014-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS. | PFIZER LTD (GB) | 1995-01-25 | — | — | EP | claimed |
| CN-1024198-C | Adenosine derivatives and their preparation | GLAXO GROUP LTD (GB) | 1994-04-13 | — | — | CN | claimed |
| WO-1993021177-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| US-5032583-A | Cardiovascular disorders | GLAXO GROUP LIMITED (GB) | 1991-07-16 | — | — | US | claimed |
| CN-1035295-A | Adenosine derivative | GLAXO GROUP LTD (GB) | 1989-09-06 | — | — | CN | claimed |
| EP-0322242-A2 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 1989-06-28 | — | — | EP | claimed |
| US-4217361-A | Disubstituted xanthone-2-carboxylic acid antiallergy agents | SYNTEX (U.S.A.) INC. (US) | 1980-08-12 | — | — | US | claimed |